172 related articles for article (PubMed ID: 35177036)
1. Functional interaction between S100A1 and MDM2 may modulate p53 signaling in normal and malignant endometrial cells.
Nakagawa M; Higuchi S; Hashimura M; Oguri Y; Matsumoto T; Yokoi A; Ishibashi Y; Ito T; Saegusa M
BMC Cancer; 2022 Feb; 22(1):184. PubMed ID: 35177036
[TBL] [Abstract][Full Text] [Related]
2. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.
Dowarha D; Chou RH; Yu C
PLoS One; 2020; 15(6):e0234152. PubMed ID: 32497081
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway.
Saegusa M; Hashimura M; Suzuki E; Yoshida T; Kuwata T
Am J Pathol; 2012 Aug; 181(2):684-92. PubMed ID: 22698986
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
5. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
7. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
8. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
9. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
10. P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.
Jiang Z; Xu W; Dan G; Liu Y; Xiong J
Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
[TBL] [Abstract][Full Text] [Related]
11. Mouse double minute homologue 2 (MDM2) downregulation by miR-661 impairs human endometrial epithelial cell adhesive capacity.
Winship A; Ton A; Van Sinderen M; Menkhorst E; Rainczuk K; Griffiths M; Cuman C; Dimitriadis E
Reprod Fertil Dev; 2018 Mar; 30(3):477-486. PubMed ID: 28847363
[TBL] [Abstract][Full Text] [Related]
12. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis.
Liu K; Xue B; Bai G; Zhang W
Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
14. S100 proteins interact with the N-terminal domain of MDM2.
van Dieck J; Lum JK; Teufel DP; Fersht AR
FEBS Lett; 2010 Aug; 584(15):3269-74. PubMed ID: 20591429
[TBL] [Abstract][Full Text] [Related]
15. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
16. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2.
García JF; Piris MA; Lloret E; Orradre JL; Murillo PG; Martínez JC
Histopathology; 1997 Feb; 30(2):120-5. PubMed ID: 9067734
[TBL] [Abstract][Full Text] [Related]
17. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
19. CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.
Liu L; Yang L; Chang H; Chen YN; Zhang F; Feng S; Peng J; Ren CC; Zhang XA
Int J Oncol; 2019 Mar; 54(3):942-954. PubMed ID: 30628640
[TBL] [Abstract][Full Text] [Related]
20. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
